All In Biotech

Drug Trial Radar · NCT07940075

SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension.

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Aug 11, 2026

Primary completion

Jan 31, 2027

Study completion Oct 31, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II clinical trial, involving multiple subcutaneous injections, aimed to evaluate the efficacy, safety, pharmacokinetic (PK), PD, and immunogenicity characteristics of SYH2062 injection in patients with mild to moderate essential hypertension.

Conditions

  • Mild to Moderate Primary Hypertension

Interventions

  • SYH2062Drug

    SYH 2062 Injection

  • PlaceboDrug

    Placebo Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in 24-hour ambulatory blood pressure (mSBP) from baseline at week 12 post-treatmentTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital Affiliated to Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.